Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.14
TEVJF's Cash to Debt is ranked lower than
53% of the 897 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. TEVJF: 0.14 )
TEVJF' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 0.14

Equity to Asset 0.51
TEVJF's Equity to Asset is ranked higher than
61% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. TEVJF: 0.51 )
TEVJF' s 10-Year Equity to Asset Range
Min: 0.39   Max: 0.6
Current: 0.51

0.39
0.6
Interest Coverage 5.25
TEVJF's Interest Coverage is ranked higher than
53% of the 544 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 101.25 vs. TEVJF: 5.25 )
TEVJF' s 10-Year Interest Coverage Range
Min: 3.6   Max: 328.25
Current: 5.25

3.6
328.25
F-Score: 8
Z-Score: 2.43
M-Score: -2.57
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 17.38
TEVJF's Operating margin (%) is ranked higher than
87% of the 850 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.26 vs. TEVJF: 17.38 )
TEVJF' s 10-Year Operating margin (%) Range
Min: 8.12   Max: 26.78
Current: 17.38

8.12
26.78
Net-margin (%) 13.38
TEVJF's Net-margin (%) is ranked higher than
86% of the 850 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.98 vs. TEVJF: 13.38 )
TEVJF' s 10-Year Net-margin (%) Range
Min: 5.73   Max: 21.09
Current: 13.38

5.73
21.09
ROE (%) 11.95
TEVJF's ROE (%) is ranked higher than
85% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.83 vs. TEVJF: 11.95 )
TEVJF' s 10-Year ROE (%) Range
Min: 4.23   Max: 27
Current: 11.95

4.23
27
ROA (%) 5.83
TEVJF's ROA (%) is ranked higher than
81% of the 903 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.02 vs. TEVJF: 5.83 )
TEVJF' s 10-Year ROA (%) Range
Min: 2.26   Max: 13.11
Current: 5.83

2.26
13.11
ROC (Joel Greenblatt) (%) 38.12
TEVJF's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 898 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.80 vs. TEVJF: 38.12 )
TEVJF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 12.89   Max: 49.79
Current: 38.12

12.89
49.79
Revenue Growth (%) 10.90
TEVJF's Revenue Growth (%) is ranked higher than
79% of the 730 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. TEVJF: 10.90 )
TEVJF' s 10-Year Revenue Growth (%) Range
Min: 7.8   Max: 23.4
Current: 10.9

7.8
23.4
EBITDA Growth (%) -10.40
TEVJF's EBITDA Growth (%) is ranked higher than
59% of the 688 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. TEVJF: -10.40 )
TEVJF' s 10-Year EBITDA Growth (%) Range
Min: -10.4   Max: 47.2
Current: -10.4

-10.4
47.2
EPS Growth (%) -25.60
TEVJF's EPS Growth (%) is ranked higher than
58% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.00 vs. TEVJF: -25.60 )
TEVJF' s 10-Year EPS Growth (%) Range
Min: -25.6   Max: 69.8
Current: -25.6

-25.6
69.8
» TEVJF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with TEVJF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 17.90
TEVJF's P/E(ttm) is ranked higher than
91% of the 939 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.60 vs. TEVJF: 17.90 )
TEVJF' s 10-Year P/E(ttm) Range
Min: 10.53   Max: 1042.5
Current: 17.9

10.53
1042.5
P/B 2.08
TEVJF's P/B is ranked higher than
82% of the 939 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.52 vs. TEVJF: 2.08 )
TEVJF' s 10-Year P/B Range
Min: 1.37   Max: 5.57
Current: 2.08

1.37
5.57
P/S 2.39
TEVJF's P/S is ranked higher than
80% of the 939 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.92 vs. TEVJF: 2.39 )
TEVJF' s 10-Year P/S Range
Min: 1.58   Max: 5.94
Current: 2.39

1.58
5.94
PFCF 16.26
TEVJF's PFCF is ranked higher than
96% of the 939 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TEVJF: 16.26 )
TEVJF' s 10-Year PFCF Range
Min: 8.45   Max: 47.95
Current: 16.26

8.45
47.95
EV-to-EBIT 16.11
TEVJF's EV-to-EBIT is ranked higher than
86% of the 939 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.45 vs. TEVJF: 16.11 )
TEVJF' s 10-Year EV-to-EBIT Range
Min: 11.7   Max: 991
Current: 16.11

11.7
991
Shiller P/E 22.41
TEVJF's Shiller P/E is ranked higher than
90% of the 939 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 141.81 vs. TEVJF: 22.41 )
TEVJF' s 10-Year Shiller P/E Range
Min: 14.08   Max: 78.77
Current: 22.41

14.08
78.77
Current Ratio 1.19
TEVJF's Current Ratio is ranked higher than
52% of the 882 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.42 vs. TEVJF: 1.19 )
TEVJF' s 10-Year Current Ratio Range
Min: 1.06   Max: 2.95
Current: 1.19

1.06
2.95
Quick Ratio 0.80
TEVJF's Quick Ratio is ranked higher than
50% of the 882 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. TEVJF: 0.80 )
TEVJF' s 10-Year Quick Ratio Range
Min: 0.68   Max: 2.19
Current: 0.8

0.68
2.19

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.22
TEVJF's Dividend Yield is ranked higher than
75% of the 517 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.35 vs. TEVJF: 2.22 )
TEVJF' s 10-Year Dividend Yield Range
Min: 0.18   Max: 2.76
Current: 2.22

0.18
2.76
Dividend Payout 0.36
TEVJF's Dividend Payout is ranked higher than
78% of the 939 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.28 vs. TEVJF: 0.36 )
TEVJF' s 10-Year Dividend Payout Range
Min: 0.04   Max: 5
Current: 0.36

0.04
5
Dividend growth (3y) 17.60
TEVJF's Dividend growth (3y) is ranked higher than
89% of the 370 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. TEVJF: 17.60 )
TEVJF' s 10-Year Dividend growth (3y) Range
Min: -6.7   Max: 80.9
Current: 17.6

-6.7
80.9
Yield on cost (5-Year) 5.45
TEVJF's Yield on cost (5-Year) is ranked higher than
93% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.44 vs. TEVJF: 5.45 )
TEVJF' s 10-Year Yield on cost (5-Year) Range
Min: 0.45   Max: 6.84
Current: 5.45

0.45
6.84
Share Buyback Rate 2.60
TEVJF's Share Buyback Rate is ranked higher than
91% of the 605 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -1.30 vs. TEVJF: 2.60 )
TEVJF' s 10-Year Share Buyback Rate Range
Min: 2.6   Max: -10.9
Current: 2.6

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 0.92
TEVJF's Price/DCF (Projected) is ranked higher than
96% of the 939 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.94 vs. TEVJF: 0.92 )
TEVJF' s 10-Year Price/DCF (Projected) Range
Min: 0.59   Max: 29.17
Current: 0.92

0.59
29.17
Price/Median PS Value 0.71
TEVJF's Price/Median PS Value is ranked higher than
94% of the 939 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.31 vs. TEVJF: 0.71 )
TEVJF' s 10-Year Price/Median PS Value Range
Min: 0.47   Max: 1.76
Current: 0.71

0.47
1.76
Earnings Yield (Greenblatt) 6.20
TEVJF's Earnings Yield (Greenblatt) is ranked higher than
86% of the 878 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. TEVJF: 6.20 )
TEVJF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 8.6
Current: 6.2

0.1
8.6
Forward Rate of Return (Yacktman) -3.51
TEVJF's Forward Rate of Return (Yacktman) is ranked higher than
64% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.06 vs. TEVJF: -3.51 )
TEVJF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2.7   Max: 48.6
Current: -3.51

-2.7
48.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:TEVA.USA, TEV.Germany, TEVA.Israel
Teva Pharmaceutical Industries Ltd was incorporated in Israel on February 13, 1944. The Company manufactures generic pharmaceutical products. It operates in business in two segments such as generic products, which includes chemical and therapeutic equivalents of originator pharmaceuticals in a variety of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants, as well as API business; and specialty products, which includes several core franchises, medicines for CNS disorders (with a strong emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines, as well as other areas such as oncology and women's health. In addition to these two segments, the Company has other activities, primarily PGT Healthcare, OTC joint venture with P&G, distribution services primarily in Israel and Hungary, and sales of medical devices. The Company, along with its subsidiaries operates in approximately 60 countries. It develops, manufactures and sell generic pharmaceutical products in a variety of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants. Specialty medicines business, which is focused on delivering solutions to patients and providers via medicines, devices and services in all key regions and markets around the world, includes several core therapeutic areas, medicines for CNS disorders (with a strong emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines. Some of its products are Copaxone, Azilect & Provigil, among others. The Company markets approximately 375 generic products in more than 1,100 dosage strengths and packaging sizes, including oral, injectables and inhaled products. The Company is subject to extensive regulation by the United States federal government, principally by the FDA and the Drug Enforcement Administration ("DEA").

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK